Dublin’s Alkermes Plc (NASDAQ:ALKS) is gearing up to file its experimental schizophrenia medication with the FDA by the third quarter of this year. The company said in a statement Tuesday that Phase-III results, which demonstrated the impact of the monthly injection, are behind its submission plans. Alkermes Plc (NASDAQ:ALKS) shares after opening at $44.21 on last trade day and at the end of the day closed at $42.08. Company price to sales ratio in past twelve months was calculated as 10.70 and price to cash ratio as 16.75. Alkermes Plc (NASDAQ:ALKS) showed a negative weekly performance of -6.96%.
Qunar Cayman Islands Ltd (NASDAQ:QUNR) rose Tuesday after Bloomberg reported that it is in merger talks with another Chinese travel site, Ctrip.com International. Bloomberg reports the two entities are discussing multiple options, including a full-blown merger and a partnership. The talks are in the early stages and may not lead to a final deal, according to Bloomberg’s two anonymous sources. The ownership structure and financing methods have also not been determined yet. Qunar Cayman Islands Ltd (NASDAQ:QUNR) shares advanced 14.65% in last trading session and ended the day on $30.84. QUNR return on equity ratio is recorded as -48.30% and its return on assets is -17.10%.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced the pricing of its previously announced public offering of 1,600,000 shares of its common stock at a public offering price of $64.00 per share. After deducting underwriting discounts and commissions and estimated offering expenses, Pacira will receive net proceeds of approximately $96.0 million in the offering. In addition, Pacira has granted the underwriters a 30-day option to purchase up to 240,000 additional shares of common stock. The offering is expected to close on or about April 14, 2014, subject to customary closing conditions. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares moved up 2.89% in last trading session and was closed at $65.45, while trading in range of $60.46 – $65.81. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) year to date (YTD) performance is 13.85%.
Intrexon Corp (NYSE:XON) CEO Randal Kirk purchased 243,001 shares of the company’s stock on the open market in a transaction that occurred on Thursday, March 27th. The shares were purchased at an average cost of $25.72 per share, for a total transaction of $6,249,985.72.Intrexon Corp (NYSE:XON) weekly performance is -7.32%. On last trading day company shares ended up $23.67. Intrexon Corp (NYSE:XON) distance from 50-day simple moving average (SMA50) is 15.92%. Analysts mean target price for the company is $31.75.
Leave a Reply